Key facts
- Cenos Therapeutics’s last known valuation is $24.0M (Jan 2025).
- It has raised $10.8M; the latest was Seed Round ($8.4M) in Jan 2025.
- Notable investors include Cure Ventures, UCB Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Cenos Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cenos Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cenos Therapeutics
Developer of a blood-brain barrier shuttle platform based in Boston, Massachusetts. The company combines innovative delivery technologies with comprehensive therapeutic development expertise, enabling healthcare professionals to drive meaningful impact for patients for the treatment of neurological diseases.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Ownership
- Privately Held (backing)
Cenos Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cenos Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cenos Therapeutics in its N-PORT filings yet. We sweep new filings monthly.